Stefan Stender1, Ruth Frikke-Schmidt2, Børge G Nordestgaard3, Anne Tybjærg-Hansen4. 1. Copenhagen University Hospitals and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark. 2. Copenhagen University Hospitals and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen, Denmark. 3. Copenhagen University Hospitals and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen, Denmark; Department of Clinical Biochemistry, Herlev Hospital, Copenhagen, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark. 4. Copenhagen University Hospitals and Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark; The Copenhagen General Population Study, Herlev Hospital, Copenhagen, Denmark; The Copenhagen City Heart Study, Frederiksberg Hospital, Copenhagen, Denmark. Electronic address: anne.tybjaerg.hansen@regionh.dk.
Abstract
OBJECTIVES: The study sought to test the hypothesis that genetic variation in ABCG5/8, the transporter responsible for intestinal and hepatobiliary cholesterol efflux, may simultaneously influence plasma and biliary cholesterol levels, and hence risk of myocardial infarction (MI) and gallstone disease in opposite directions. BACKGROUND: High plasma levels of low-density lipoprotein (LDL) cholesterol are a causal risk factor for MI, whereas high levels of biliary cholesterol promote gallstone formation. METHODS: A total of 60,239 subjects from Copenhagen were included, including 5,647 with MI and 3,174 with symptomatic gallstone disease. Subjects were genotyped for 6 common, nonsynonymous and functional variants in ABCG5/8, and a combined weighted genotype score was calculated. RESULTS: Combined, weighted genotype scores were associated with stepwise decreases in LDL cholesterol of up to 5.9% (0.20 mmol/l) for individuals with a score ≥8.0 (prevalence = 11%) versus <2.0 (prevalence = 9%; p for trend across 5 groups = 2 × 10E-35). The cumulative incidences of MI and gallstone disease as a function of age and increasing genotype score were decreased and increased (log-rank ps for trend: 6 × 10E-4 and 9 × 10E-45), respectively. The multifactorially adjusted odds ratios were 0.83 (95% confidence interval: 0.73 to 0.94) for MI and 2.85 (95% confidence interval: 2.39 to 3.39) for symptomatic gallstone disease for individuals with a genotype score ≥8.0 versus <2.0. CONCLUSIONS: Genetic variation in ABCG5/8, which associates with decreased levels of plasma LDL cholesterol protects against MI, but increases the risk of symptomatic gallstone disease. These results suggest that MI and gallstones, 2 seemingly unrelated diseases, are intrinsically linked via the function of the ABCG5/8 cholesterol transporter.
OBJECTIVES: The study sought to test the hypothesis that genetic variation in ABCG5/8, the transporter responsible for intestinal and hepatobiliary cholesterol efflux, may simultaneously influence plasma and biliary cholesterol levels, and hence risk of myocardial infarction (MI) and gallstone disease in opposite directions. BACKGROUND: High plasma levels of low-density lipoprotein (LDL) cholesterol are a causal risk factor for MI, whereas high levels of biliary cholesterol promote gallstone formation. METHODS: A total of 60,239 subjects from Copenhagen were included, including 5,647 with MI and 3,174 with symptomatic gallstone disease. Subjects were genotyped for 6 common, nonsynonymous and functional variants in ABCG5/8, and a combined weighted genotype score was calculated. RESULTS: Combined, weighted genotype scores were associated with stepwise decreases in LDL cholesterol of up to 5.9% (0.20 mmol/l) for individuals with a score ≥8.0 (prevalence = 11%) versus <2.0 (prevalence = 9%; p for trend across 5 groups = 2 × 10E-35). The cumulative incidences of MI and gallstone disease as a function of age and increasing genotype score were decreased and increased (log-rank ps for trend: 6 × 10E-4 and 9 × 10E-45), respectively. The multifactorially adjusted odds ratios were 0.83 (95% confidence interval: 0.73 to 0.94) for MI and 2.85 (95% confidence interval: 2.39 to 3.39) for symptomatic gallstone disease for individuals with a genotype score ≥8.0 versus <2.0. CONCLUSIONS: Genetic variation in ABCG5/8, which associates with decreased levels of plasma LDL cholesterol protects against MI, but increases the risk of symptomatic gallstone disease. These results suggest that MI and gallstones, 2 seemingly unrelated diseases, are intrinsically linked via the function of the ABCG5/8 cholesterol transporter.
Authors: Amit D Joshi; Charlotte Andersson; Stephan Buch; Stefan Stender; Raymond Noordam; Lu-Chen Weng; Peter E Weeke; Paul L Auer; Bernhard Boehm; Constance Chen; Hyon Choi; Gary Curhan; Joshua C Denny; Immaculata De Vivo; John D Eicher; David Ellinghaus; Aaron R Folsom; Charles Fuchs; Manish Gala; Jeffrey Haessler; Albert Hofman; Frank Hu; David J Hunter; Harry L A Janssen; Jae H Kang; Charles Kooperberg; Peter Kraft; Wolfgang Kratzer; Wolfgang Lieb; Pamela L Lutsey; Sarwa Darwish Murad; Børge G Nordestgaard; Louis R Pasquale; Alex P Reiner; Paul M Ridker; Eric Rimm; Lynda M Rose; Christian M Shaffer; Clemens Schafmayer; Rulla M Tamimi; André G Uitterlinden; Uwe Völker; Henry Völzke; Yoshiyuki Wakabayashi; Janey L Wiggs; Jun Zhu; Dan M Roden; Bruno H Stricker; Weihong Tang; Alexander Teumer; Jochen Hampe; Anne Tybjærg-Hansen; Daniel I Chasman; Andrew T Chan; Andrew D Johnson Journal: Gastroenterology Date: 2016-04-16 Impact factor: 22.682
Authors: Anna Helgadottir; Gudmar Thorleifsson; Kristjan F Alexandersson; Vinicius Tragante; Margret Thorsteinsdottir; Finnur F Eiriksson; Solveig Gretarsdottir; Eythór Björnsson; Olafur Magnusson; Gardar Sveinbjornsson; Ingileif Jonsdottir; Valgerdur Steinthorsdottir; Egil Ferkingstad; Brynjar Ö Jensson; Hreinn Stefansson; Isleifur Olafsson; Alex H Christensen; Christian Torp-Pedersen; Lars Køber; Ole B Pedersen; Christian Erikstrup; Erik Sørensen; Søren Brunak; Karina Banasik; Thomas F Hansen; Mette Nyegaard; Gudmundur I Eyjolfssson; Olof Sigurdardottir; Bjorn L Thorarinsson; Stefan E Matthiasson; Thora Steingrimsdottir; Einar S Bjornsson; Ragnar Danielsen; Folkert W Asselbergs; David O Arnar; Henrik Ullum; Henning Bundgaard; Patrick Sulem; Unnur Thorsteinsdottir; Gudmundur Thorgeirsson; Hilma Holm; Daniel F Gudbjartsson; Kari Stefansson Journal: Eur Heart J Date: 2020-07-21 Impact factor: 29.983
Authors: Junghyun Lim; Janine Wirth; Kana Wu; Edward Giovannucci; Peter Kraft; Constance Turman; Mingyang Song; Manol Jovani; Andrew T Chan; Amit D Joshi Journal: Clin Gastroenterol Hepatol Date: 2021-07-02 Impact factor: 13.576
Authors: Stefan Stender; Julia Kozlitina; Børge G Nordestgaard; Anne Tybjærg-Hansen; Helen H Hobbs; Jonathan C Cohen Journal: Nat Genet Date: 2017-04-24 Impact factor: 38.330